Jazz Pharmaceuticals plc (JAZZ) Institutional Ownership & Insider Trading

643 institutions reported holding Jazz Pharmaceuticals plc shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 61 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

JAZZJazz Pharmaceuticals plcFollow JAZZ — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 13.9B
P/E TTM: 14.6
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

643 institutions held 99.2% of the shares. Across filers that reported both quarters, shares held changed -2.0%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	643	64	-2.0%	221	113	168	43
Mar 26	568	65	+3.6%	203	66	150	68
Dec 25	566	63	+1.5%	156	99	184	38
Sep 25	490	61	-0.6%	142	45	178	42
Jun 25	497	62	+4.0%	167	46	159	85
Mar 25	537	59	+1.2%	192	78	139	44
Dec 24	498	59	-0.8%	156	57	158	41
Sep 24	465	57	-0.4%	150	55	138	44

Jazz Pharmaceuticals plc — questions

Who owns Jazz Pharmaceuticals plc stock?: 643 institutions reported Jazz Pharmaceuticals plc shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (9.2%), FMR LLC (7.1%), VANGUARD PORTFOLIO MANAGEMENT LLC (4.7%).
Are Jazz Pharmaceuticals plc insiders buying or selling?: 61 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Jazz Pharmaceuticals plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.